common.study.topics.clinical

Testing Experimental Medication in Healthy Subjects

common.study.values.description

A Study of LY3502970 in Healthy Participants

The main purposes of this study are to determine: - The safety of LY3502970 and any side effects that might be associated with it. - How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 4 parts (A, B, C, and D). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B involves multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - LY3502970

Administered orally.

Drug - Placebo

Administered orally.

Drug - Atorvastatin

Administered orally.

Drug - Simvastatin

Administered orally.

Drug - Midazolam

Administered orally.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects

common.study.values.clinical-trial-id

NCT03929744

participant.views.study.view.id

eVO9oa